It has 5 products in preclinical phases in addition to Campath that is waiting for the FDA green light for the treatment of lymphoid leukemia. In Phase II for Crohn s disease and in Phase II also, for ulcerative colitis. In Phase II for cancer. LDP-977 in Phase II for asthma. In between the hands of partners, including Bayer, several products are being scrutinized for development in addition to many therapeutic targets waiting for therapeutic molecules.
Millennium is a giant.
Not only because it is building itself into a giant, modern and extremely advanced pharmaceutical company, but also because it managed to do all this with only 16 cents loss per share. Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities.